Immunomedics (IMMU) PT Raised to $31 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts IMMU Hot Sheet
Price: $87.86 --0%
Rating Summary:
13 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
13 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on Immunomedics (NASDAQ: IMMU) to $31.00 (from $23.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- First Financial Bancorp (FFBC) PT Lowered to $37 at Raymond James
- Bausch Health Companies (BHC) PT Raised to $8 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
